Short answer
Biogen (BIIB) filed an 8-K current report with the SEC on July 1, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 GAAP and non-GAAP EPS expected to include approximately $164 million of pre-tax milestone-related expense.
Biogen 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 GAAP and non-GAAP EPS expected to include approximately $164 million of pre-tax milestone-related expense
- Q2 EPS impact estimated at approximately $0.95 per diluted share
- Q3 2026 potential milestones and transactions could add $290–$320 million of expense
- Q3 EPS impact estimated at $1.75–$1.95 per diluted share
- Q2 results remain preliminary and subject to financial statement closing procedures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biogen 8-K filings
Get the next BIIB 8-K as it lands
Follow BIIB for push alerts, or ask the research agent what this filing means.